Cargando…
Varicella zoster immune globulin (human) (VARIZIG) in immunocompromised patients: a subgroup analysis for safety and outcomes from a large, expanded-access program
BACKGROUND: Immunocompromised children and adults are at increased risk for severe disease and death following varicella zoster virus infection. Varicella zoster immune globulin (human) (VARIZIG) is recommended for post-exposure prophylaxis to prevent or attenuate varicella infection in high-risk in...
Autores principales: | Gans, Hayley, Chemaly, Roy F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798258/ https://www.ncbi.nlm.nih.gov/pubmed/33430796 http://dx.doi.org/10.1186/s12879-020-05656-6 |
Ejemplares similares
-
Safety and Varicella Outcomes in In Utero–Exposed Newborns and Preterm Infants Treated With Varicella Zoster Immune Globulin (VARIZIG): A Subgroup Analysis of an Expanded-Access Program
por: Duchon, Jennifer M, et al.
Publicado: (2019) -
Varicella zoster immune globulin (VARIZIG) administration up to 10 days after varicella exposure in pregnant women, immunocompromised participants, and infants: Varicella outcomes and safety results from a large, open-label, expanded-access program
por: Levin, Myron J., et al.
Publicado: (2019) -
2479. Varicella Zoster Immune Globulin Is Effective up to 10 Days Following Varicella Exposure in Pregnant Women, Immunocompromised Patients, and Infants: Results From a Large, Open-Label Expanded-Access Program
por: Levin, Myron, et al.
Publicado: (2018) -
Preventing varicella zoster infection in immunocompromised adults with varicella zoster–specific immunoglobulins
por: Gelman, Daniel, et al.
Publicado: (2023) -
Central nervous system varicella zoster vasculopathy in an immunocompromised patient
por: Guedes, Mariana, et al.
Publicado: (2018)